Affluent Medical SA (FR:CVX)
:CVX
Want to see FR:CVX full AI Analyst Report?
CVX Stock Chart & Stats
€3.01
-€0.01(-0.72%)
At close: 4:00 PM EST
€3.01
-€0.01(-0.72%)
Day’s Range― - ―
52-Week Range€1.16 - €5.22
Previous CloseN/A
VolumeN/A
Average Volume (3M)9.49K
Market Cap
€183.58M
Enterprise Value€144.00M
Total Cash (Recent Filing)€1.76M
Total Debt (Recent Filing)€24.04M
Price to Earnings (P/E)―
Beta0.77
Next Earnings
Sep 24, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.64
Shares Outstanding59,243,675
10 Day Avg. Volume9,769
30 Day Avg. Volume9,492
Financial Highlights & Ratios
PEG Ratio-0.04
Price to Book (P/B)12.26
Price to Sales (P/S)0.00
P/FCF Ratio-5.81
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€5.00Price Target Upside66.11% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.46
Revenue Forecast (FY)€2.06M
Bulls Say, Bears Say
Bulls Say
Diversified Device PipelineAffluent Medical’s portfolio targets multiple structural and vascular indications (mitral valve, aneurysm sealing, urinary sphincter). That diversification reduces single-product dependency, increases potential regulatory/commercial pathways across markets, and raises the chance that at least one program reaches commercialization over a multi-quarter horizon.
Milestone-driven Medtech Business ModelAs a development-stage medtech, the company’s model focuses on R&D and staging clinical/regulatory milestones. This typical milestone-driven approach can efficiently create value via licensing, partnerships, or staged financing, enabling progress without immediate commercial revenue and aligning incentives with long-term regulatory success.
Substantial Asset Base And Focused TeamThe combination of a meaningful asset base and a specialized, lean team (66 employees) supports sustained R&D and clinical program execution. These durable operational resources increase the firm's capacity to run trials, iterate device designs, and manage regulatory processes over many quarters, improving execution odds.
Bears Say
No Reported Revenue In 2025Recording zero revenue for 2025 indicates the company has not yet commercialized products. Over the medium term this means continued reliance on funding until regulatory approvals and sales occur; absent a clear near-term commercialization path, sustainable cash generation remains highly uncertain.
Persistent Heavy Cash BurnConsistent negative operating and free cash flow shows that reported losses translate into real cash outflows. This persistent cash burn materially raises financing needs, increases dilution or debt risk, and could delay programs if external funding is constrained, threatening continuity of development programs over multiple quarters.
Deteriorating Leverage And Eroded EquityRising debt alongside collapsing equity weakens the balance sheet, reducing financial flexibility to fund trials or partner on favorable terms. Higher leverage elevates refinancing and covenant risk and may increase cost of capital, constraining strategic options and making successful long-term program completion more challenging.
Affluent Medical SA News
CVX FAQ
What was Affluent Medical SA’s price range in the past 12 months?
Affluent Medical SA lowest stock price was €1.16 and its highest was €5.22 in the past 12 months.
What is Affluent Medical SA’s market cap?
Affluent Medical SA’s market cap is €183.58M.
When is Affluent Medical SA’s upcoming earnings report date?
Affluent Medical SA’s upcoming earnings report date is Sep 24, 2026 which is in 121 days.
How were Affluent Medical SA’s earnings last quarter?
Currently, no data Available
Is Affluent Medical SA overvalued?
According to Wall Street analysts Affluent Medical SA’s price is currently Undervalued.
Does Affluent Medical SA pay dividends?
Affluent Medical SA does not currently pay dividends.
What is Affluent Medical SA’s EPS estimate?
Affluent Medical SA’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Affluent Medical SA have?
Affluent Medical SA has 59,243,675 shares outstanding.
What happened to Affluent Medical SA’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Affluent Medical SA?
Currently, no hedge funds are holding shares in FR:CVX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Affluent Medical SA
Carvolix is a medical technologies company in the commercial and clinical stage, which engages in the provision of structural heart disease and brain stroke treatment. It develops AI- and imaging-driven mini-robots that make complex procedures and biomimetic heart valves. The company was founded on January 30, 2026 and is headquartered in Aix-en-Provence, France.
CVX Stock 12 Month Forecast
Average Price Target
€5.00
▲(66.11% Upside)